Sanofi Diagnostics expects Access Chlamydia to achieve 20-25% U.S. share in 2-3 years.
This article was originally published in The Gray Sheet
Executive Summary
SANOFI ACCESS CHLAMYDIA IMMUNOASSAY $7-8 MIL. IN ANNUAL U.S. SALES expected within two to three years, the company projects. The test was commercially introduced to the U.S. on May 22, shortly after it received FDA 510(k) clearance. Sanofi Diagnostics Pasteur expects the Access Chlamydia, which generates revenue for Sanofi of about $3.50 per test, to gain a 20-25% share of the U.S. chlamydia test market within that time frame. The U.S. chlamydia market, currently at $30 mil., is growing at about 10% a year, the company estimates.